Lobbying Filing Details

Total Spending

$1,000,000

Activities

3

Lobbyists

3

Gov't Entities

6

Filing Information
Filing UUID:
367a81a6-4bb7-43e9-8069-40a41492d693
Type:
Q4 - 4th Quarter - Report
Period:
2013 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 21, 2014 at 10:14 PM
Income:
$0
Expenses:
$1,000,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Debbie Garza, Divisional Vice President Government and Community Relations
Registrant
WALGREEN COMPANY

Retail Pharmacy

WASHINGTON, District of Columbia
Client
WALGREEN COMPANY
District of Columbia, United States of America
Lobbying Activities (3)
Activity 1
Consumer Issues/Safety/Products

S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Medicare/Medicaid

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend Title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.

Issues related to expansion of the role of a pharmacist federally in health care delivery. No specific legislation

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Pharmacy

S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing
responsibilities of state and federal authorities.S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

Lobbyists (3)
  • DEBBIE GARZA
  • ALETHIA JACKSON
  • MR. EDWARD KALETA III
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.